secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2026-08-06T12:02:17+00:00
Accession:  0001628280-26-053878
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q2 net loss $42.1M; IND/CTA clearances for PM577a, arbitration win for PM647
--------------------------------------------------------------------------------

- Net loss of $42.1M for Q2 2026 vs $52.6M in Q2 2025; R&D expenses $33.4M.
- Cash, equivalents, investments, restricted cash $108.8M as of June 30, 2026; runway into 2027.
- FDA cleared IND for PM577a in Wilson disease; Medsafe cleared CTA in New Zealand; global Phase 1/2 study startup underway.
- Arbitration with Beam Therapeutics resolved favorably; PM647 rights secured; IND/CTA submission expected Q3 2026.
- FDA granted RMAT designation to PM359 for CGD; BLA submission planned for 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/0001628280-26-053878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/prme-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer